Diagnostic value of (18)F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a metaanalysis
- PMID: 20150275
- DOI: 10.2967/jnumed.109.066217
Diagnostic value of (18)F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a metaanalysis
Erratum in
- J Nucl Med. 2010 Aug;51(8):1327
Abstract
We assessed the diagnostic performance of (18)F-FDG PET in detecting paraaortic lymph node (PALN) metastasis in patients with cervical cancer.
Methods: Through a search of MEDLINE and EMBASE (1980 to March 2009), we performed a random-effects meta analysis. A summary receiver-operating-characteristic curve was constructed using hierarchical regression models. To identify other sources of heterogeneity, regression meta analysis was performed.
Results: Patients (n = 385) from 10 studies were analyzed. Although specificity of (18)F-FDG PET was consistent (97%; 95% confidence interval [CI], 93%-99%), sensitivity was low and heterogeneous among the studies (34%; 95% CI, 10%-72%). Although regression meta analysis did not identify any source to which heterogeneity could be attributed, it revealed a trend of increasing sensitivity according to an increase in the prevalence of PALN metastasis (P = 0.001). In the 5 studies with prevalence greater than 15%, estimated sensitivity and specificity were 73% (95% CI, 53%-87%) and 93% (95% CI, 86%-97%), respectively. With the diagnostic performance, assuming the prevalence of 15%, the calculated false-positive and -negative rates were 35% and 5%, respectively.
Conclusion: In detecting PALN metastasis, PET performs acceptably only in populations with a relatively high probability of PALN metastasis. Otherwise, we found no evidence to justify the evaluation of PALN based solely on PET in cervical cancer.
Similar articles
-
Prospective evaluation of 18-fluoro-2-deoxy-D-glucose positron emission tomography for the discrimination of paraaortic nodal spread in patients with locally advanced cervical carcinoma.Int J Gynecol Cancer. 2013 Jan;23(1):170-5. doi: 10.1097/IGC.0b013e3182784289. Int J Gynecol Cancer. 2013. PMID: 23196756 Clinical Trial.
-
A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy.Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):477-84. doi: 10.1016/j.ijrobp.2009.02.020. Epub 2009 May 21. Int J Radiat Oncol Biol Phys. 2010. PMID: 19464824 Clinical Trial.
-
18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis.J Natl Cancer Inst. 2008 May 21;100(10):712-20. doi: 10.1093/jnci/djn125. Epub 2008 May 13. J Natl Cancer Inst. 2008. PMID: 18477804
-
Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients.J Nucl Med. 2003 Nov;44(11):1775-83. J Nucl Med. 2003. PMID: 14602859
-
A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.Eur J Radiol. 2012 May;81(5):1007-15. doi: 10.1016/j.ejrad.2011.01.126. Epub 2011 Feb 26. Eur J Radiol. 2012. PMID: 21354739 Review.
Cited by
-
Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.Jpn J Radiol. 2014 Jun;32(6):313-23. doi: 10.1007/s11604-014-0317-x. Epub 2014 Apr 18. Jpn J Radiol. 2014. PMID: 24744135 Review.
-
The type of metastasis is a prognostic factor in disseminated cervical cancer.J Gynecol Oncol. 2010 Sep;21(3):186-90. doi: 10.3802/jgo.2010.21.3.186. Epub 2010 Sep 28. J Gynecol Oncol. 2010. PMID: 20922142 Free PMC article.
-
Debulking metastatic pelvic nodes before radiotherapy in cervical cancer patients: a long-term follow-up result.Int J Clin Oncol. 2011 Oct;16(5):546-52. doi: 10.1007/s10147-011-0225-3. Epub 2011 Mar 25. Int J Clin Oncol. 2011. PMID: 21437570
-
Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting.Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1353-66. doi: 10.1007/s00259-010-1717-5. Epub 2011 Jan 12. Eur J Nucl Med Mol Imaging. 2011. PMID: 21225421 Review.
-
Diagnostic performance of whole-body [18F]FDG PET/MR in cancer M staging: A systematic review and meta-analysis.Eur Radiol. 2024 Jan;34(1):673-685. doi: 10.1007/s00330-023-10009-3. Epub 2023 Aug 3. Eur Radiol. 2024. PMID: 37535156